Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-SLV187 in Advanced Parkinson's Disease
NCT01479127Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at Day 21, Potentially Clinically Significant Hematology Results at Day 21 and 5 more. Started Oct 2011; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01479127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479127.